Oct 16
Earnings call
Q2 2027 earnings call
Solara Active Pharma Sciences Limited reported revenue growth of 33% year-on-year, base-business revenue growth of 37% to 327 crores, and EBITDA margin expansion to 18.4% from 11%. It expects to close the ibuprofen strategic review in 12 weeks.